MTOR and cancer: Next, RCC4B20 cells were assessed for cross-resistance to alternative PI3K-AKT-mTOR inhibitors, to determine whether the resistance was driven by altered response to PI3K, mTORC1 or mTORC kinase inhibition, and whether relevant to other anti-cancer agents in development.